The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.

To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through ...

Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD).

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

The rising global incidence of breast cancer, driven by lifestyle changes and an aging population, is a key market driver. Technological advancements in diagnostics and treatment, such as molecular ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...